---
layout: post
title: "Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:00:39 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-19501
original_published: 2022-09-09 00:00:00 +0000
significance: 8.00
---

# Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:00 UTC
**Source:** Federal Register
**Original Published:** September 09, 2022 00:00 UTC
**Document Number:** 2022-19501

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products." This draft guidance is intended to assist industry in providing information in labeling about the quantities at which sodium, potassium, and phosphorus as constituents of active or inactive drug ingredients are present in human over-the-counter (OTC) and prescription drug products.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/09/09/2022-19501/quantitative-labeling-of-sodium-potassium-and-phosphorus-for-human-over-the-counter-and-prescription)
- API: https://www.federalregister.gov/api/v1/documents/2022-19501

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
